---
title: "Oncotype"
slug: "oncotype"
date: "2023-10-26"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Breast Cancer Molecular Subtyping]]

# Oncotype

- å®‰å¯å¾… (Oncotype DX)
- 21 å€‹åŸºå› ï¼Œä¸¦ä»¥ PCR çš„ â†’ æ–¹å¼ä¾†è¨ˆç®—çŸ³è Ÿ åŒ…åŸ‹æª¢é«”ä¸­çš„åŸºå› è¡¨ç¾é‡ï¼Œåˆ†åˆ¥æ–¼ 2015ã€2018 å¹´ç™¼è¡¨æ–¼æ–°è‹±æ ¼è˜­é†«å­¸é›œèªŒçš„ TAILORx ç ”ç©¶æ”¶æ¡ˆ
- 10273 åä¹³ç™Œç—…äººç‚º HR é™½æ€§ã€HER2 é™°æ€§ã€æ·‹å·´è…º âœ– ç„¡è½‰ç§»è€…ï¼Œ
- æ¬¡åˆ†çµ„åˆ†æžé¡¯ç¤ºå¾©ç™¼è©•åˆ†å€¼ (Recurrence Score ) 0-10 åˆ†å±¬ä½Žå¾©ç™¼é¢¨éšªè€…ï¼Œ

  - è‹¥åƒ…æŽ¥å—æŠ—è·çˆ¾è’™æ²»ç™‚è€Œæ²’ä½¿ç”¨åŒ–å­¸æ²»ç™‚ç¶“äº”å¹´è¿½è¹¤çš„ â†’
  - çµæžœï¼Œæ²’æœ‰ç™¼ç”Ÿé ç«¯è½‰ç§»è¶…éŽ 99%ï¼Œç¸½å­˜æ´»çŽ‡ 98% ( ç¬¬ä¸€ç´šè­‰æ“š )ï¼Œ
  - é¡¯ç¤ºä½Žå¾©ç™¼è©•åˆ†è€…å¯ä»¥é¿å…åŒ–å­¸æ²»ç™‚åƒ…ä½¿ç”¨è·çˆ¾è’™æ²»ç™‚å°±æœ‰æ¥µä½³çš„äº”å¹´å­˜æ´»çŽ‡ã€‚

  - Recurrence Score 11-25 åˆ† è€… ( ä¸­ å¾© ç™¼ é¢¨ éšª ) è¢« éš¨ æ©Ÿåˆ†æ´¾åŒ–å­¸æ²»ç™‚ - è·çˆ¾è’™æ²»ç™‚åŠåƒ…æœ‰è·çˆ¾è’™æ²»ç™‚çµ„ï¼Œ çµæžœåƒ…ç”¨è·çˆ¾è’™æ²»ç™‚çµ„ä¸¦ âœ– ä¸æœƒæ¯”åŒ–å­¸æ²»ç™‚ - è·çˆ¾è’™æ²» ç™‚çµ„å·®

- ç„¶è€Œå¿…é ˆæŒ‡å‡ºï¼Œå°æ–¼ 50 æ­²ä»¥ä¸‹çš„ â†’ å¹´è¼•å¥³æ€§ Recurrence Score åœ¨ 16-25 ä¹‹é–“è€…ï¼ŒåŒ–å­¸æ²»ç™‚å¯èƒ½æœƒæœ‰æ‰€ å¹«åŠ©ï¼Œå€¼å¾—æ…Žæ€
- Recurrence Score> 26 åˆ†è€…ï¼ˆé«˜å¾©ç™¼é¢¨éšªï¼‰é ˆæŽ¥å—åŒ–å­¸æ²»ç™‚ã€‚
  ç¶œåˆ [[TAILORx]] ç ”ç©¶çµæžœæŒ‡å‡ºï¼ŒHR é™½æ€§ã€HER2 é™°æ€§ã€ æ·‹å·´è…º âœ– ç„¡è½‰ç§»ï¼Œå¯ä»¥ â˜¢ é¿å…åŒ–å­¸æ²»ç™‚ç´„ä½” 70% çš„ â†’ ç—…äººã€‚
- ä¸å¿…æŽ¥å—åŒ–å­¸æ²»ç™‚çš„ â†’ æ¢ä»¶å¦‚ä¸‹ï¼š 1) å¹´é½¡å¤§æ–¼ 50 æ­²ä¸”å¾©ç™¼è©•åˆ†å€¼ç‚º 11 ~ 25 2) ä¸ç®¡å¹´é½¡ï¼Œå¾©ç™¼è©•åˆ†å€¼ç‚º 0~10 3) å¹´é½¡å°æ–¼ 50 æ­²ï¼Œå¾©ç™¼è©•åˆ†å€¼ç‚º 11 ~ 15
- åœ¨ HR é™½æ€§ã€HER2 é™°æ€§ã€æ·‹å·´è…º âœ– ç„¡è½‰ç§»ç—…äººä¸­ï¼Œ ä»æœ‰ 30ï¼…ç—…äººéœ€è¦æŽ¥å—åŒ–å­¸æ²»ç™‚ï¼Œæ¢ä»¶å¦‚ä¸‹ï¼š 1) ä»»ä½•å¹´é½¡å¾©ç™¼è©•åˆ†å€¼ç‚º 26 ~ 100 åˆ† 2) 50 æ­²æˆ–ä»¥ä¸‹ï¼Œå¾©ç™¼è©•åˆ†å€¼ç‚º 16~25 åˆ†

### References

> [Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa1804710)
